Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719381 | 0.85 | SLC6A4 (0.41) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21621554 | 0.85 | SLC6A4 (0.45) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20703659 | 0.83 | KDM4E (0.50) | HDAC1HDAC6MAPTCA12CA1 | |
| SCHEMBL31024720 | 0.83 | CA12 (0.46) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17724093 | 0.83 | CA12 (0.46) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27433790 | 0.83 | CA12 (0.50) | NPC1SMN1; SMN2HDAC1HDAC6MAPT | |
| SCHEMBL1997531 | 0.82 | CES2 (0.61) | CES2CES1SLC6A4SLC6A3NPC1 | |
| SCHEMBL21000818 | 0.81 | GAA (0.42) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21198962 | 0.81 | NOTUM (0.42) | SLC6A3HDAC1HDAC6MAPTCA12 | |
| SCHEMBL18765520 | 0.81 | ABL1 (0.45) | SLC6A4SLC6A3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11040960-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10988464-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3377059-B1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2020-05-07 | — | — | US | disclosed |
| US-20200039969-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10370363-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10336736-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9834545-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834545-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9809581-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809581-B2 | Inhibitors of CXCR2 | CHEMOCENTRYX, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144997-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144997-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988464-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-10336736-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-20200039969-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-20170144997-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-20170144996-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | CES2 3922/4885CES1 4005/4885SLC6A4 4533/4885 |
| US-20200140418-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | CES2 3922/4885CES1 4005/4885SLC6A4 4533/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-10370363-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | CES2 3922/4885CES1 4005/4885SLC6A4 4533/4885 |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | CES2 2738/4885CES1 2855/4885SLC6A4 3089/4885 |
| US-11040960-B2 | Inhibitors of CXCR2 | CXCR2, CXCR3, CXCR1 | CES2 3922/4885CES1 4005/4885SLC6A4 4533/4885 |
| US-20180170916-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR3, CXCR1 | CES2 3920/4885CES1 4004/4885SLC6A4 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.